$LUNG
Pulmonx Corp Stock $lung

$lung Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000112753721000008 Filed on March 15, 2021

Income Statement

Concept	2020 Q4	2019 Q4	2019 Q3
Revenue	$9.830M	$10.35M	$9.104M
YoY Change	-5.0%
Cost Of Revenue	$2.750M	$3.010M	$2.697M
YoY Change	-8.64%
Gross Profit	$7.078M	$7.337M	$6.407M
YoY Change	-3.53%
Gross Profit Margin	72.0%	70.91%	70.38%
Selling, General & Admin	$13.96M	$10.02M	$8.621M
YoY Change	39.32%
% of Gross Profit	197.23%	136.57%	134.56%
Research & Development	$2.470M	$1.600M	$1.399M
YoY Change	54.38%
% of Gross Profit	34.9%	21.81%	21.84%
Depreciation & Amortization	$120.0K	$120.0K	$100.0K
YoY Change	0.0%
% of Gross Profit	1.7%	1.64%	1.56%
Operating Expenses	$16.43M	$11.63M	$10.02M
YoY Change	41.27%
Operating Profit	-$9.352M	-$4.293M	-$3.613M
YoY Change	117.84%
Interest Expense	-$250.0K	-$630.0K	$460.0K
YoY Change	-60.32%
% of Operating Profit
Other Income/Expense, Net	$330.0K	$400.0K	-$340.0K
YoY Change	-17.5%
Pretax Income	-$9.280M	-$4.520M	-$4.246M
YoY Change	105.31%
Income Tax	$20.00K	$150.0K	$89.00K
% Of Pretax Income
Net Earnings	-$9.297M	-$4.669M	-$4.335M
YoY Change	99.12%
Net Earnings / Revenue	-94.58%	-45.12%	-47.62%
Basic Earnings Per Share
Diluted Earnings Per Share	-$913.6K	-$137.6K	-$127.9K
COMMON SHARES
Basic Shares Outstanding	35.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$231.6M	$28.35M
YoY Change	716.88%
Cash & Equivalents	$231.6M	$14.77M	$15.73M
Short-Term Investments	$0.00	$13.58M
Other Short-Term Assets	$377.0K	$766.0K
YoY Change	-50.78%
Inventory	$10.74M	$5.612M
Prepaid Expenses
Receivables	$4.228M	$5.511M
Other Receivables	$400.0K
Total Short-Term Assets	$250.0M	$41.07M
YoY Change	508.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.474M	$902.0K
YoY Change	63.41%
Goodwill	$2.300M	$2.300M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$536.0K	$579.0K
YoY Change	-7.43%
Total Long-Term Assets	$13.72M	$12.46M
YoY Change	10.09%
TOTAL ASSETS
Total Short-Term Assets	$250.0M	$41.07M
Total Long-Term Assets	$13.72M	$12.46M
Total Assets	$263.7M	$53.53M
YoY Change	392.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.472M	$2.681M
YoY Change	-45.1%
Accrued Expenses	$8.651M	$9.463M
YoY Change	-8.58%
Deferred Revenue	$71.00K	$173.0K
YoY Change	-58.96%
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$12.53M	$14.16M
YoY Change	-11.55%
LONG-TERM LIABILITIES
Long-Term Debt	$17.40M
YoY Change
Other Long-Term Liabilities	$7.600M
YoY Change
Total Long-Term Liabilities	$25.00M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.53M	$14.16M
Total Long-Term Liabilities	$25.00M
Total Liabilities	$37.57M	$35.57M
YoY Change	5.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$242.7M	-$210.5M
YoY Change	15.31%
Common Stock	$467.2M	$21.75M
YoY Change	2047.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$226.1M	-$187.4M	-$182.8M
YoY Change
Total Liabilities & Shareholders Equity	$263.7M	$53.53M
YoY Change	392.61%

Cashflow Statement

Concept	2020 Q4	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	-$9.297M	-$4.669M	-$4.335M
YoY Change	99.12%
Depreciation, Depletion And Amortization	$120.0K	$120.0K	$100.0K
YoY Change	0.0%
Cash From Operating Activities	-$7.260M	-$3.480M	-$4.240M
YoY Change	108.62%
INVESTING ACTIVITIES
Capital Expenditures	-$690.0K	-$220.0K	-$340.0K
YoY Change	213.64%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$3.250M	-$16.76M
YoY Change	-100.0%
Cash From Investing Activities	-$700.0K	$3.030M	-$17.10M
YoY Change	-123.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	199.8M	-420.0K	310.0K
YoY Change	-47661.9%
NET CHANGE
Cash From Operating Activities	-7.260M	-3.480M	-4.240M
Cash From Investing Activities	-700.0K	3.030M	-17.10M
Cash From Financing Activities	199.8M	-420.0K	310.0K
Net Change In Cash	191.8M	-870.0K	-21.03M
YoY Change	-22145.98%
FREE CASH FLOW
Cash From Operating Activities	-$7.260M	-$3.480M	-$4.240M
Capital Expenditures	-$690.0K	-$220.0K	-$340.0K
Free Cash Flow	-$6.570M	-$3.260M	-$3.900M
YoY Change	101.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001127537
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q4	dei	Entity Public Float EntityPublicFloat	0	USD
CY2020Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	100000
CY2020Q3	lung	Lessee Operating Sublease Renewal Term LesseeOperatingSubleaseRenewalTerm	P12M
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-39562
CY2020	dei	Entity Registrant Name EntityRegistrantName	PULMONX CORPORATION
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0424412
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	700 Chesapeake Drive
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
CY2020	dei	Country Region CountryRegion	1
CY2020	dei	City Area Code CityAreaCode	650
CY2020	dei	Local Phone Number LocalPhoneNumber	364-0400
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2020	dei	Trading Symbol TradingSymbol	LUNG
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q4	us-gaap	Assets Assets	53533000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1472000	USD
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35689881	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	231561000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14767000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	231000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	13580000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4228000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5511000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	10741000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	5612000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3228000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1601000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	249989000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	41071000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1474000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	902000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	2333000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	2333000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	400000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	524000	USD
CY2020Q4	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2019Q4	us-gaap	Deferred Costs DeferredCosts	1563000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8976000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6561000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	536000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	579000	USD
CY2020Q4	us-gaap	Assets Assets	263708000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	173000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2238000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	446000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2681000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8651000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9463000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	94000	USD
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	233000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000	USD
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1165000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12526000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14161000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	62000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	43000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7618000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6403000	USD
CY2020Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	564000	USD
CY2019Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	0	USD
CY2020Q4	us-gaap	Medium Term Notes MediumTermNotes	16804000	USD
CY2019Q4	us-gaap	Medium Term Notes MediumTermNotes	14965000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	37574000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	35572000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	177985811	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	17583150	shares
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	17583150	shares
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2019Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	210610000	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	205339000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35693753	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35693753	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2100203	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2100203	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	467147000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	21750000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1685000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1373000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20004000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242734000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-210503000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	226134000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-187378000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	263708000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53533000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32733000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32595000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11531000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10181000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7718000	USD
CY2020	us-gaap	Gross Profit GrossProfit	21202000	USD
CY2019	us-gaap	Gross Profit GrossProfit	22414000	USD
CY2018	us-gaap	Gross Profit GrossProfit	12286000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7460000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6049000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6991000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46074000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34203000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20347000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	53534000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	40252000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	27338000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-32332000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-17838000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-15052000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	213000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	432000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	21000	USD
CY2020	us-gaap	Interest Expense InterestExpense	3181000	USD
CY2019	us-gaap	Interest Expense InterestExpense	2317000	USD
CY2018	us-gaap	Interest Expense InterestExpense	2520000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3282000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20703000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-18479000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	318000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	40000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-617000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-916000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32018000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20340000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18467000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	213000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	363000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32231000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	34000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	126000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-6000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	312000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	126000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31919000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20663000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18353000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.16
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-11.66
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-11.03
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10184841	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1776110	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1674779	shares
CY2017Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	12641035	shares
CY2017Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	140452000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-149394000	USD
CY2018	lung	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	7884	shares
CY2018	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	83000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	31000	USD
CY2018	lung	Adjustments To Additional Paid In Capital Change In Shares Subject To Repurchase AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase	24000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	366000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	126000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-18479000	USD
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	12648919	shares
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	140535000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-167326000	USD
CY2019	lung	Adjustments To Temporary Equity Stock Issued Issuance Costs AdjustmentsToTemporaryEquityStockIssuedIssuanceCosts	329000	USD
CY2019	lung	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	4934231	shares
CY2019	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	64804000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	528000	USD
CY2019	lung	Adjustments To Additional Paid In Capital Change In Shares Subject To Repurchase AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase	-281000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	364000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	34000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20703000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	17583150	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	205339000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-187378000	USD
CY2020	lung	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	213876	shares
CY2020	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	2260000	USD
CY2020	lung	Temporary Equity Decrease Conversion Of Convertible Securities Shares TemporaryEquityDecreaseConversionOfConvertibleSecuritiesShares	17797026	shares
CY2020	lung	Temporary Equity Decrease Conversion Of Convertible Securities Value TemporaryEquityDecreaseConversionOfConvertibleSecuritiesValue	207599000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	207599000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	201392000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2705000	USD
CY2020	lung	Adjustments To Additional Paid In Capital Change In Shares Subject To Repurchase AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase	-346000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3489000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	318000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-6000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32231000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	226134000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32231000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20703000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-18479000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3197000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	364000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	366000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-12000	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12000	USD
CY2020	lung	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	-3190000	USD
CY2019	lung	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	523000	USD
CY2018	lung	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	642000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-7000	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-4000	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-15000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	472000	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	332000	USD
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	297000	USD
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	483000	USD
CY2019	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	365000	USD
CY2018	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	270000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	968000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	28000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	36000	USD
CY2020	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	3030000	USD
CY2019	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	0	USD
CY2018	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	0	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	35000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	61000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	0	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	32000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	0	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1756000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1467000	USD
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	836000	USD
CY2018	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1457000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2524000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	262000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5047000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2613000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1245000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	684000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-21000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-65000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-18000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	592000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	524000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-648000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1019000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3375000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	928000	USD
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-155000	USD
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	182000	USD
CY2018	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-34000	USD
CY2020	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2019	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2018	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	62000	USD
CY2020	lung	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-876000	USD
CY2019	lung	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-692000	USD
CY2018	lung	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-22000	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	5000	USD
CY2018	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	200000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-108000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	33000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-39000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30633000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20765000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18394000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	21450000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	13605000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	7937000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	500000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	911000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	720000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	316000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	16000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12694000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14233000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	200000	USD
CY2020	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	17291000	USD
CY2019	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	0	USD
CY2020	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	17248000	USD
CY2019	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	0	USD
CY2018	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	0	USD
CY2020	lung	Payments Of Debt Fees PaymentsOfDebtFees	1875000	USD
CY2019	lung	Payments Of Debt Fees PaymentsOfDebtFees	0	USD
CY2018	lung	Payments Of Debt Fees PaymentsOfDebtFees	0	USD
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2019	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	6000000	USD
CY2018	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	12000000	USD
CY2020	lung	Proceeds From Issuance Of Temporary Equity ProceedsFromIssuanceOfTemporaryEquity	0	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	32950000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6000000	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	12000000	USD
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	2666000	USD
CY2019	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	USD
CY2018	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	USD
CY2020	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	2666000	USD
CY2019	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	USD
CY2018	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	162000	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2462000	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	568000	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2019	lung	Payments For Temporary Equity Issuance Costs PaymentsForTemporaryEquityIssuanceCosts	329000	USD
CY2019	lung	Proceeds From Issuance Of Temporary Equity ProceedsFromIssuanceOfTemporaryEquity	39671000	USD
CY2018	lung	Proceeds From Issuance Of Temporary Equity ProceedsFromIssuanceOfTemporaryEquity	0	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2261000	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	83000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2705000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	528000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31000	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	201392000	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	21000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	12000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	234831000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45619000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12114000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	133000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	217025000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10643000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5926000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14767000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4124000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10050000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231792000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14767000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4124000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	231561000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14767000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4124000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	231000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231792000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14767000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4124000	USD
CY2020	lung	Increase Lapse In Repurchase Of Common Stock Rights IncreaseLapseInRepurchaseOfCommonStockRights	-346000	USD
CY2019	lung	Increase Lapse In Repurchase Of Common Stock Rights IncreaseLapseInRepurchaseOfCommonStockRights	-281000	USD
CY2018	lung	Increase Lapse In Repurchase Of Common Stock Rights IncreaseLapseInRepurchaseOfCommonStockRights	24000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	65000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	47000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2020	lung	Accrued Interest On Convertible Debt AccruedInterestOnConvertibleDebt	0	USD
CY2019	lung	Accrued Interest On Convertible Debt AccruedInterestOnConvertibleDebt	496000	USD
CY2018	lung	Accrued Interest On Convertible Debt AccruedInterestOnConvertibleDebt	738000	USD
CY2020	lung	Issuance Of Derivative Instrument For Convertible Debt IssuanceOfDerivativeInstrumentForConvertibleDebt	3900000	USD
CY2019	lung	Issuance Of Derivative Instrument For Convertible Debt IssuanceOfDerivativeInstrumentForConvertibleDebt	0	USD
CY2018	lung	Issuance Of Derivative Instrument For Convertible Debt IssuanceOfDerivativeInstrumentForConvertibleDebt	0	USD
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	25133000	USD
CY2018	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2020	lung	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	USD
CY2019	lung	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	995000	USD
CY2018	lung	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	USD
CY2020	lung	Deposit For Operating Lease Not Yet Paid DepositForOperatingLeaseNotYetPaid	0	USD
CY2019	lung	Deposit For Operating Lease Not Yet Paid DepositForOperatingLeaseNotYetPaid	231000	USD
CY2018	lung	Deposit For Operating Lease Not Yet Paid DepositForOperatingLeaseNotYetPaid	0	USD
CY2020	lung	Right Of Use Asset Recorded Upon Adoption Of Accounting Standards Update RightOfUseAssetRecordedUponAdoptionOfAccountingStandardsUpdate	0	USD
CY2019	lung	Right Of Use Asset Recorded Upon Adoption Of Accounting Standards Update RightOfUseAssetRecordedUponAdoptionOfAccountingStandardsUpdate	1181000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3935000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6216000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	259000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	196000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	226000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	3059000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	1396000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1361000	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	Formation and Business of the Company<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonx Corporation (the “Company”) was incorporated in the state of California in December 1995 as Pulmonx and reincorporated in the state of Delaware in December 2013. The Company is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat a broad pool of patients for whom medical management has reached its limits and either do not want or are ineligible for surgical approaches. The Company has subsidiaries in the Cayman Islands, Germany, Switzerland, Australia, the United Kingdom, the Netherlands, Italy, France and Hong Kong.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2020, the Company’s registration statement on Form S-1 (File No. 333-248635) relating to its initial public offering (“IPO”) of common stock became effective. The IPO closed on October 5, 2020 at which time the Company issued 11,500,000 shares of its common stock at a price of $19.00 per share, which included the issuance of shares in connection with the exercise by the underwriters of their option to purchase up to 1,500,000 additional shares. The Company received an aggregate of $218.5 million gross proceeds, before underwriting discounts, commissions and offering costs, and approximately $201.4 million in net proceeds after deducting underwriting discounts and commissions and offering costs. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon closing the IPO, all outstanding shares of the Company’s convertible preferred stock converted into 17,797,026 shares of common stock. Additionally, the $33.0 million aggregate outstanding principal amount and $0.8 million accrued interest of the 2020 Notes converted into 2,561,484 shares of common stock at a conversion price of $13.20 per share. In connection with the completion of its IPO, on October 5, 2020, the Company’s certificate of incorporation was amended and restated to provide for 200,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses and negative cash flows from operations to date and has an accumulated deficit of $242.7 million as of December 31, 2020. During the years ended December 31, 2020, 2019 and 2018, the Company used $30.6 million, $20.8 million and $18.4 million of cash in its operating activities, respectively. As of December 31, 2020, the Company had cash and cash equivalents of $231.6 million. Historically, the Company’s activities have been financed through private placements of equity securities, debt and sale of common stock in the IPO.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company’s existing cash and cash equivalents will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been actively monitoring the novel coronavirus, or COVID-19, situation and its impact. In response to the pandemic, numerous state and local jurisdictions imposed “shelter-in-place” orders, quarantines and other restrictions. In the markets in which we operate, elective, specialty and other procedures and appointments have been suspended or canceled. In March 2020, the governor of California, where the Company’s headquarters are located, issued “stay at home” orders limiting non-essential activities, travel and business operations. Such orders or restrictions have resulted in reduced operations at the Company’s headquarters (including manufacturing facility), </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">work stoppages, slowdowns and delays, travel restrictions and cancellation of events and have restricted the efforts of the Company’s sales representatives, thereby significantly and adversely impacting the Company’s operations. These orders and restrictions have significantly delayed and decreased the number of procedures performed using the Company’s products and otherwise adversely impacted sales and operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements reflect judgments and estimates that could change in the future as a result of the COVID-19 pandemic. The COVID-19 pandemic has adversely impacted the Company’s business, financial condition and results of operations by decreasing and delaying substantially all procedures performed using the its products, and the Company expects the pandemic to continue to adversely impact its business, financial condition and results of operations for the foreseeable future.</span></div>
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242700000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30600000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20800000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18400000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	231600000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions include reserves and write-downs related to inventories, the recoverability of long term assets, valuation of equity instruments and equity-linked instruments, valuation of common stock, stock-based compensation, valuation of the convertible preferred stock warrant liability and derivative liabilities, intangible assets, goodwill, debt and related features, deferred tax assets and related valuation allowances and impact of contingencies.</span></div>
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of December 31, 2020 and 2019, the Company also had cash on deposit with foreign banks of approximately $5.6 million and $5.2 million, respectively, that was not federally insured.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company earns revenue from the sale of its products to distributors and other customers such as hospitals. Sales of Zephyr Valves and delivery catheters accounted for most of our revenue for the years ended December 31, 2020, 2019 and 2018. The Company’s accounts receivable are derived from revenue earned from distributors and customers. The Company performs ongoing credit evaluations of its customers’ and distributors’ financial condition and generally requires no collateral from its customers and distributors. At December 31, 2020 and 2019, no customer or distributor accounted for more than 10% of accounts receivable. For the years ended December 31, 2020, 2019 and 2018, no customer or distributor accounted for more than 10% of revenue.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on single source suppliers for the components, sub-assemblies and materials for its products. These components, sub-assemblies and materials are critical and there are no or relatively few alternative sources of supply. The Company’s suppliers have generally met the Company’s demand for their products and services on a timely basis in the past.</span></div>
CY2020Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	5600000	USD
CY2019Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	5200000	USD
CY2019Q4	us-gaap	Deferred Costs DeferredCosts	1600000	USD
CY2020	lung	Write Off Of Deferred Offering Costs WriteOffOfDeferredOfferingCosts	3000000.0	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1800000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	100000	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	segment
CY2020	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	100000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	100000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	200000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	200000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	200000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	1500000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	600000	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	100000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	100000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-100000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-300000	USD
CY2019Q4	lung	Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost	14574000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	USD
CY2019Q4	lung	Cash Cash Equivalents And Available For Sale Debt Securities CashCashEquivalentsAndAvailableForSaleDebtSecurities	14580000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	13580000	USD
CY2019Q4	lung	Cash Cash Equivalents And Available For Sale Debt Securities CashCashEquivalentsAndAvailableForSaleDebtSecurities	14580000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	100000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	10533000	USD
CY2020	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	The Company valued the 2020 Notes derivative liability using the “with and without” methodology. The “with and without” methodology involves valuing the convertible note on an as is basis and then valuing the 2020 Notes without each individual embedded derivative. The difference between the value of the 2020 Notes with the embedded derivatives and the value without each individual embedded derivative equals the fair value of that embedded derivative. In April 2020, the Company valued the embedded derivatives using a Monte Carlo Simulation (“MCS”). The first step of each simulation was to forecast the Company’s Series G-1 convertible preferred stock price through the expiration of the 2020 Notes. In order to estimate the future share price of the Series G-1 convertible preferred stock, the Company applied a “random walk” model based upon a Geometric Brownian Motion process with a constant drift.
CY2020Q4	us-gaap	Cash Cash	221028000	USD
CY2019Q4	us-gaap	Cash Cash	7449000	USD
CY2019Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	6318000	USD
CY2020Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	0	USD
CY2019Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	1000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	231561000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14767000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3342000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1950000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	227000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	180000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7172000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3482000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	10741000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	5612000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3247000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	381000	USD
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	436000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2131000	USD
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	12000	USD
CY2020Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	339000	USD
CY2019Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	387000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	377000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	766000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3228000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1601000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2342000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1773000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1440000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1474000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	902000	USD
CY2020	us-gaap	Depreciation Depreciation	300000	USD
CY2019	us-gaap	Depreciation Depreciation	200000	USD
CY2018	us-gaap	Depreciation Depreciation	100000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	2300000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	2300000	USD
CY2020Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2020	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	0	USD
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2020	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	0	USD
CY2020Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1849000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1449000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	400000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1849000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1325000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	524000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	123000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	123000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	521000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	123000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	31000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	400000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2374000	USD
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3064000	USD
CY2020Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1810000	USD
CY2019Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1098000	USD
CY2020Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	1368000	USD
CY2019Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	705000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1313000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1342000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1708000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	17146000	USD
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	762000	USD
CY2020Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	629000	USD
CY2019Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	304000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	636000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	480000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8651000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9463000	USD
CY2020Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	3900000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	723000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	564000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18433000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	196000	USD
CY2020Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	869000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	17368000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q3	lung	Operating Lease Monthly Expense OperatingLeaseMonthlyExpense	100000	USD
CY2020Q3	lung	Operating Lease Expense Annual Increase Rate OperatingLeaseExpenseAnnualIncreaseRate	0.035
CY2020Q3	lung	Tenant Improvement Allowance Receivable Upon Lease Renewal TenantImprovementAllowanceReceivableUponLeaseRenewal	200000	USD
CY2013	lung	Lessee Operating Lease Option To Terminate Notice Period LesseeOperatingLeaseOptionToTerminateNoticePeriod	P12M
CY2020Q2	lung	Lessee Operating Sublease Term LesseeOperatingSubleaseTerm	P3Y
CY2020Q2	lung	Lessee Operating Sublease Option To Terminate Notice Period LesseeOperatingSubleaseOptionToTerminateNoticePeriod	P180D
CY2020Q2	lung	Lessee Operating Sublease Option To Terminate Term LesseeOperatingSubleaseOptionToTerminateTerm	P18M
CY2020Q2	lung	Lessee Operating Sublease Option To Terminate Term LesseeOperatingSubleaseOptionToTerminateTerm	P18M
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	337000	USD
CY2020Q2	lung	Lessee Operating Sublease Monthly Expense LesseeOperatingSubleaseMonthlyExpense	100000	USD
CY2020Q2	lung	Lessee Operating Sublease Expense Annual Increase Rate LesseeOperatingSubleaseExpenseAnnualIncreaseRate	0.035
CY2020Q3	lung	Lessee Operating Sublease Term LesseeOperatingSubleaseTerm	P4Y
CY2020Q3	lung	Lessee Operating Sublease Monthly Expense LesseeOperatingSubleaseMonthlyExpense	100000	USD
CY2020Q3	lung	Lessee Operating Sublease Expense Annual Increase Rate LesseeOperatingSubleaseExpenseAnnualIncreaseRate	0.035
CY2020Q3	lung	Lessee Operating Sublease Tenant Improvement Allowance Receivable Upon Lease Renewal LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal	600000	USD
CY2020Q3	lung	Lessee Operating Sublease Term LesseeOperatingSubleaseTerm	P4Y
CY2020Q4	lung	Number Of Vehicle Leases NumberOfVehicleLeases	2	lease
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1000000.0	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2078000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1037000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	12000	USD
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	13000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	234000	USD
CY2020	us-gaap	Lease Cost LeaseCost	2427000	USD
CY2019	us-gaap	Lease Cost LeaseCost	1284000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2769000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2069000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2795000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2589000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1007000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11229000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1373000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9856000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2238000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7618000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8976000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6561000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5940000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32018000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M17D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y6M14D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.061
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1494000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	893000	USD
CY2020	lung	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Including Adoption Of Accounting Standards Update RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdoptionOfAccountingStandardsUpdate	3935000	USD
CY2019	lung	Right Of Use Asset Obtained In Exchange For Operating Lease Liability Including Adoption Of Accounting Standards Update RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityIncludingAdoptionOfAccountingStandardsUpdate	7316000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-28029000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-17142000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-12527000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3989000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3198000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20340000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18467000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	9000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	10000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	185000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	358000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	207000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	194000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	368000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	209000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	6000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	7000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-222000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	6000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	27000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	7000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-39000	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	21000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	19000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-197000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	213000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	363000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.102
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.027
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.010
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.039
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.048
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.080
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.006
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.006
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.009
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.004
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.029
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.405
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.209
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.107
CY2020	lung	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Carryforwards And Credits EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwardsAndCredits	0.000
CY2019	lung	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Carryforwards And Credits EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwardsAndCredits	0.000
CY2018	lung	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Carryforwards And Credits EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwardsAndCredits	-0.225
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Restructuring Charges EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges	0.119
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Restructuring Charges EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges	0.000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Restructuring Charges EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges	0.000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.007
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.018
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30400000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22500000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19519000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5240000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4896000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4659000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6675000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1926000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	850000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	42315000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29322000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	25028000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41922000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28953000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24736000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	393000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	369000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	292000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	27000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	23000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	17000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	428000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	389000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	323000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	62000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	43000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	48000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41900000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13000000.0	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4200000	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-2000000.0	USD
CY2018	lung	Operating Loss Carryforward Valuation Allowance Increase Decrease OperatingLossCarryforwardValuationAllowanceIncreaseDecrease	-3100000	USD
CY2018	lung	Tax Credit Carryforward Valuation Allowance Increase Decrease TaxCreditCarryforwardValuationAllowanceIncreaseDecrease	-1200000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8200000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1070000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	57000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	185000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	942000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	47000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	989000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	7259000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8248000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.57
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	215291000	shares
CY2019Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2018Q1	lung	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	7884	shares
CY2018Q1	lung	Temporary Equity Exercise Price TemporaryEquityExercisePrice	10.57
CY2018Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	100000	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	430588	shares
CY2019Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	215291	shares
CY2020Q1	lung	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	213876	shares
CY2020Q1	lung	Temporary Equity Exercise Price TemporaryEquityExercisePrice	10.57
CY2020Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	2300000	USD
CY2020Q1	lung	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	1415	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2019Q2	lung	Temporary Equity Stock Issued During Period Value New Issues Price Per Share TemporaryEquityStockIssuedDuringPeriodValueNewIssuesPricePerShare	13.20
CY2019Q2	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	40000000.0	USD
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	177985811	shares
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	17583150	shares
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	17583150	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	205339000	USD
CY2019Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	210610000	USD
CY2020Q4	lung	Temporary Equity Liquidation Preference Percentage Of Ownership Before Transaction Threshold TemporaryEquityLiquidationPreferencePercentageOfOwnershipBeforeTransactionThreshold	0.50
CY2020Q4	lung	Number Of Votes For Each Share Of Common Stock Held NumberOfVotesForEachShareOfCommonStockHeld	1	vote
CY2020Q4	lung	Number Of Members Of Board Of Directors NumberOfMembersOfBoardOfDirectors	7	member
CY2020	lung	Temporary Equity Conversion Of Stock Covenant Minimum Aggregate Cash Proceeds From Sale Of Stock TemporaryEquityConversionOfStockCovenantMinimumAggregateCashProceedsFromSaleOfStock	30000000.0	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2020	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2020Q4	lung	Number Of Votes For Each Share Of Common Stock Held NumberOfVotesForEachShareOfCommonStockHeld	1	vote
CY2019	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	414	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6877197	shares
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	21155368	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2419948	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.52
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	255900	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	255900	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.37
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18153	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.68
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	31201	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.53
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2626494	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.51
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1078957	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1078957	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.93
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	390318	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.35
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	35809	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.39
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3279324	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.66
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1466071	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1466071	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.73
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1745040	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.55
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.79
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.70
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	76952	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.55
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2923403	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.72
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2000000.0	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.72
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.72
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	188000000.0	USD
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	188000000.0	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.66
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.66
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10900000	USD
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	10900000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1219241	shares
CY2020Q4	lung	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice	2.03
CY2020	lung	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P5Y2M23D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2923403	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.72
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M17D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	81700000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	7600000	USD
CY2020	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	10000	shares
CY2019	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	9147	shares
CY2020	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	100000	USD
CY2019	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	100000	USD
CY2020Q4	lung	Share Based Payment Arrangement Shares Subject To Repurchase Aggregate Exercise Price ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice	600000	USD
CY2019Q4	lung	Share Based Payment Arrangement Shares Subject To Repurchase Aggregate Exercise Price ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice	300000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1466071	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1078957	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	255900	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.78
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3197000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	364000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	366000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3197000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	364000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	366000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	300000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	USD
CY2018	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	14800000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1900000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	300000	USD
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	400000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32231000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20703000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18479000	USD
CY2020	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	10341809	shares
CY2019	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1796233	shares
CY2018	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1706654	shares
CY2020	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	156968	shares
CY2019	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	20123	shares
CY2018	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	31875	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10184841	shares
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32595000	USD
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1776110	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1674779	shares
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.16
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-11.66
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-11.03
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32733000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20004000	USD
CY2020Q4	us-gaap	Noncurrent Assets NoncurrentAssets	1474000	USD
CY2019Q4	us-gaap	Noncurrent Assets NoncurrentAssets	902000	USD
CY2020	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	USD
CY2020	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	100000	USD
CY2019	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	100000	USD
CY2018	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	100000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8618000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3673000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10612000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9830000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	5650000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	1012000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	7462000	USD
CY2020Q4	us-gaap	Gross Profit GrossProfit	7078000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-7163000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-11911000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-3860000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-9297000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.76
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.15
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.37
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5778000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7366000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9104000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10347000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	3717000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	4953000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	6407000	USD
CY2019Q4	us-gaap	Gross Profit GrossProfit	7337000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6128000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-5571000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4335000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-4669000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.61
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.24
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.41
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.48

Files In Submission

Name	View Source	Status
0001127537-21-000008-index-headers.html	Edgar Link	pending
0001127537-21-000008-index.html	Edgar Link	pending
0001127537-21-000008.txt	Edgar Link	pending
0001127537-21-000008-xbrl.zip	Edgar Link	pending
exhibit10_13davidlehmanoff.htm	Edgar Link	pending
exhibit21_1listofsubsidiar.htm	Edgar Link	pending
exhibit23_1bdoconsentfy20.htm	Edgar Link	pending
exhibit31_1x123120.htm	Edgar Link	pending
exhibit31_2x123120.htm	Edgar Link	pending
exhibit32_1x123120.htm	Edgar Link	pending
exhibit32_2x123120.htm	Edgar Link	pending
exhibit4_3descriptionofcom.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_41a.jpg	Edgar Link	pending
lung-20201231.htm	Edgar Link	pending
lung-20201231.xsd	Edgar Link	pending
lung-20201231_cal.xml	Edgar Link	unprocessable
lung-20201231_def.xml	Edgar Link	unprocessable
lung-20201231_g1.jpg	Edgar Link	pending
lung-20201231_g10.jpg	Edgar Link	pending
lung-20201231_g11.jpg	Edgar Link	pending
lung-20201231_g12.jpg	Edgar Link	pending
lung-20201231_g13.jpg	Edgar Link	pending
lung-20201231_g14.jpg	Edgar Link	pending
lung-20201231_g15.jpg	Edgar Link	pending
lung-20201231_g16.jpg	Edgar Link	pending
lung-20201231_g17.jpg	Edgar Link	pending
lung-20201231_g18.jpg	Edgar Link	pending
lung-20201231_g19.jpg	Edgar Link	pending
lung-20201231_g2.jpg	Edgar Link	pending
lung-20201231_g20.jpg	Edgar Link	pending
lung-20201231_g21.jpg	Edgar Link	pending
lung-20201231_g22.jpg	Edgar Link	pending
lung-20201231_g23.jpg	Edgar Link	pending
lung-20201231_g24.jpg	Edgar Link	pending
lung-20201231_g25.jpg	Edgar Link	pending
lung-20201231_g26.jpg	Edgar Link	pending
lung-20201231_g27.jpg	Edgar Link	pending
lung-20201231_g28.jpg	Edgar Link	pending
lung-20201231_g29.jpg	Edgar Link	pending
lung-20201231_g3.jpg	Edgar Link	pending
lung-20201231_g30.jpg	Edgar Link	pending
lung-20201231_g31.jpg	Edgar Link	pending
lung-20201231_g32.jpg	Edgar Link	pending
lung-20201231_g33.jpg	Edgar Link	pending
lung-20201231_g34.jpg	Edgar Link	pending
lung-20201231_g35.jpg	Edgar Link	pending
lung-20201231_g36.jpg	Edgar Link	pending
lung-20201231_g37.jpg	Edgar Link	pending
lung-20201231_g4.jpg	Edgar Link	pending
lung-20201231_g5.jpg	Edgar Link	pending
lung-20201231_g6.jpg	Edgar Link	pending
lung-20201231_g7.jpg	Edgar Link	pending
lung-20201231_g8.jpg	Edgar Link	pending
lung-20201231_g9.jpg	Edgar Link	pending
lung-20201231_htm.xml	Edgar Link	completed
lung-20201231_lab.xml	Edgar Link	unprocessable
lung-20201231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUNG
Pulmonx Corp Stock $lung

2020 Q4 Form 10-K Financial Statement

#000112753721000008 Filed on March 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUNG Pulmonx Corp Stock $lung

2020 Q4 Form 10-K Financial Statement

#000112753721000008 Filed on March 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUNG
Pulmonx Corp Stock $lung